As of 2025-07-06, the EV/EBITDA ratio of Recursion Pharmaceuticals Inc (RXRX) is -3.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RXRX's latest enterprise value is 1,666.84 mil USD. RXRX's TTM EBITDA according to its financial statements is -516.84 mil USD. Dividing these 2 quantities gives us the above RXRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.2x - 12.8x | 10.5x |
| Forward P/E multiples | 11.9x - 20.6x | 16.2x |
| Fair Price | (13.96) - (15.11) | (15.84) |
| Upside | -364.9% - -386.6% | -400.5% |
| Date | EV/EBITDA |
| 2025-07-03 | -3.23 |
| 2025-07-02 | -3.18 |
| 2025-07-01 | -3.11 |
| 2025-06-30 | -3.06 |
| 2025-06-27 | -3.04 |
| 2025-06-26 | -3.33 |
| 2025-06-25 | -3.14 |
| 2025-06-24 | -3.19 |
| 2025-06-23 | -2.88 |
| 2025-06-20 | -3.04 |
| 2025-06-18 | -3.10 |
| 2025-06-17 | -2.89 |
| 2025-06-16 | -3.01 |
| 2025-06-13 | -2.95 |
| 2025-06-12 | -3.15 |
| 2025-06-11 | -3.33 |
| 2025-06-10 | -3.37 |
| 2025-06-09 | -3.30 |
| 2025-06-06 | -3.40 |
| 2025-06-05 | -2.67 |
| 2025-06-04 | -2.94 |
| 2025-06-03 | -2.53 |
| 2025-06-02 | -2.52 |
| 2025-05-30 | -2.37 |
| 2025-05-29 | -2.58 |
| 2025-05-28 | -2.54 |
| 2025-05-27 | -2.53 |
| 2025-05-23 | -2.29 |
| 2025-05-22 | -2.34 |
| 2025-05-21 | -2.30 |
| 2025-05-20 | -2.66 |
| 2025-05-19 | -2.63 |
| 2025-05-16 | -2.67 |
| 2025-05-15 | -2.42 |
| 2025-05-14 | -2.47 |
| 2025-05-13 | -2.63 |
| 2025-05-12 | -2.73 |
| 2025-05-09 | -2.49 |
| 2025-05-08 | -2.53 |
| 2025-05-07 | -2.38 |
| 2025-05-06 | -2.35 |
| 2025-05-05 | -2.82 |
| 2025-05-02 | -3.56 |
| 2025-05-01 | -3.41 |
| 2025-04-30 | -3.48 |
| 2025-04-29 | -3.58 |
| 2025-04-28 | -3.67 |
| 2025-04-25 | -3.59 |
| 2025-04-24 | -3.60 |
| 2025-04-23 | -3.47 |